Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

539
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
539
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocarboxylate transporter 2 regulates maintenance of myelin and axonal integrity by oligodendrocytes.

Nature communications·2026
Same author

From impulsivity to binge eating: the mediating influence of emotional, external, and restrictive eating styles.

Journal of eating disorders·2026
Same author

Implementation of an Intervention Program Based on Virtual Walking and Therapeutic Exercise in Cuba: A Feasibility Study.

Healthcare (Basel, Switzerland)·2026
Same author

Non-Invasive Autonomic Neuromodulation for Overactive Bladder: A Comparative Pilot Trial of NESA and Tibial Nerve Stimulation.

Journal of clinical medicine·2025
Same author

Effects of environmental enrichment during adolescence on social defeat effects.

Behavioral neuroscience·2025
Same author

Effect of virtual walking on chronic pain, tone and spasticity in incomplete spinal cord injury.

Disability and rehabilitation·2025

Related Experiment Video

Updated: Nov 11, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K

Targeting Alzheimer's disease with multimodal polypeptide-based nanoconjugates.

A Duro-Castano1, C Borrás2, V Herranz-Pérez3,4

  • 1Polymer Therapeutics Lab., Centro de Investigación Príncipe Felipe (CIPF), Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain.

Science Advances
|March 27, 2021
PubMed
Summary

Researchers developed targeted polypeptide nanoconjugates for Alzheimer's disease (AD) treatment. These nanoconjugates show neuroprotection, neurotrophic effects, and reduce amyloid aggregates in AD model mice.

More Related Videos

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.7K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.5K

Related Experiment Videos

Last Updated: Nov 11, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.7K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.5K

Area of Science:

  • Neuroscience
  • Biotechnology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is the most common dementia, currently incurable.
  • Existing pharmacological strategies for AD have limitations.
  • Developing effective treatments for AD remains a significant challenge.

Purpose of the Study:

  • To develop targeted multimodal polypeptide-based nanoconjugates for potential Alzheimer's disease (AD) treatment.
  • To evaluate the neuroprotective and neurotrophic potential of these nanoconjugates.
  • To assess the efficacy of nanoconjugates in reducing amyloid aggregates and improving cognitive function in AD models.

Main Methods:

  • Conjugation of propargylamine moieties, bisdemethoxycurcumin or genistein to polypeptide nanoconjugates.
  • Addition of Angiopep-2 targeting moiety for enhanced blood-brain barrier (BBB) passage.
  • In vitro studies using organotypic hippocampal culture to assess neuroprotection and neurotrophic effects.
  • In vivo studies using APP/PS1 transgenic AD model mice to evaluate BBB penetration, brain distribution, amyloid reduction, and cognitive function.

Main Results:

  • Polypeptide nanoconjugates demonstrated neuroprotection and neurotrophic effects, increasing dendritic density in hippocampal neurons.
  • Angiopep-2 conjugation improved BBB passage and targeted nanoconjugate accumulation in neurogenic brain areas.
  • Nanoconjugate treatment significantly reduced neurotoxic β-amyloid aggregate levels in AD model mice.
  • Treatment rescued olfactory memory and object recognition impairments in APP/PS1 mice.

Conclusions:

  • Targeted multimodal polypeptide-based nanoconjugates show promise as a novel therapeutic strategy for Alzheimer's disease.
  • These nanoconjugates possess both neuroprotective and neurotrophic properties.
  • The study highlights the potential of nanoconjugate-based drug delivery for CNS disorders like AD.